BridgeBio Pharma Inc. [NASDAQ: BBIO] price plunged by -4.49 percent to reach at -$0.61. The company report on January 13, 2022 that BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G12C Mutation.
– First clinical combination study of BBP-398 and LUMAKRAS set to evaluate safety and preliminary efficacy in solid tumors with the KRAS G12C mutation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced a non-exclusive clinical collaboration with Amgen Inc. (Amgen) to evaluate the combination of BBP-398, a potentially best-in-class SHP2 inhibitor, with LUMAKRAS® (sotorasib), a KRASG12C inhibitor, in patients with advanced solid tumors with the KRAS G12C mutation.
A sum of 2770272 shares traded at recent session while its average daily volume was at 3.24M shares. BridgeBio Pharma Inc. shares reached a high of $13.7299 and dropped to a low of $12.80 until finishing in the latest session at $12.99.
The one-year BBIO stock forecast points to a potential upside of 52.59. The average equity rating for BBIO stock is currently 1.60, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on BridgeBio Pharma Inc. [BBIO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BBIO shares is $27.40 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BBIO stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
SVB Leerink have made an estimate for BridgeBio Pharma Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on December 27, 2021. While these analysts kept the previous recommendation, Mizuho dropped their target price from $86 to $25. The new note on the price target was released on December 27, 2021, representing the official price target for BridgeBio Pharma Inc. stock. Previously, the target price had yet another raise to $75, while BofA Securities analysts kept a Buy rating on BBIO stock.
The Average True Range (ATR) for BridgeBio Pharma Inc. is set at 2.67, with the Price to Sales ratio for BBIO stock in the period of the last 12 months amounting to 34.16.
BBIO Stock Performance Analysis:
BridgeBio Pharma Inc. [BBIO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -12.94. With this latest performance, BBIO shares dropped by -65.96% in over the last four-week period, additionally sinking by -78.05% over the last 6 months – not to mention a drop of -81.37% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BBIO stock in for the last two-week period is set at 26.72, with the RSI for the last a single of trading hit 24.51, and the three-weeks RSI is set at 28.38 for BridgeBio Pharma Inc. [BBIO]. The present Moving Average for the last 50 days of trading for this stock 34.88, while it was recorded at 13.95 for the last single week of trading, and 49.35 for the last 200 days.
Insight into BridgeBio Pharma Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and BridgeBio Pharma Inc. [BBIO] shares currently have an operating margin of -5751.99. BridgeBio Pharma Inc.’s Net Margin is presently recorded at -5439.74.
Return on Total Capital for BBIO is now -80.46, given the latest momentum, and Return on Invested Capital for the company is -85.58. Return on Equity for this stock declined to -192.44, with Return on Assets sitting at -67.21. When it comes to the capital structure of this company, BridgeBio Pharma Inc. [BBIO] has a Total Debt to Total Equity ratio set at 856.19. Additionally, BBIO Total Debt to Total Capital is recorded at 89.54, with Total Debt to Total Assets ending up at 70.47. Long-Term Debt to Equity for the company is recorded at 847.12, with the Long-Term Debt to Total Capital now at 88.59.
Reflecting on the efficiency of the workforce at the company, BridgeBio Pharma Inc. [BBIO] managed to generate an average of -$1,165,517 per employee.BridgeBio Pharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.70 and a Current Ratio set at 6.70.
BridgeBio Pharma Inc. [BBIO] Insider Position Details
There are presently around $1,809 million, or 96.00% of BBIO stock, in the hands of institutional investors. The top three institutional holders of BBIO stocks are: KOHLBERG KRAVIS ROBERTS & CO. L.P. with ownership of 31,060,971, which is approximately 0% of the company’s market cap and around 3.60% of the total institutional ownership; VIKING GLOBAL INVESTORS LP, holding 26,620,991 shares of the stock with an approximate value of $345.81 million in BBIO stocks shares; and BLACKROCK INC., currently with $131.74 million in BBIO stock with ownership of nearly 6.747% of the company’s market capitalization.
Positions in BridgeBio Pharma Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 115 institutional holders increased their position in BridgeBio Pharma Inc. [NASDAQ:BBIO] by around 5,469,675 shares. Additionally, 80 investors decreased positions by around 8,001,993 shares, while 36 investors held positions by with 125,789,435 shares. The mentioned changes placed institutional holdings at 139,261,103 shares, according to the latest SEC report filing. BBIO stock had 32 new institutional investments in for a total of 1,649,041 shares, while 19 institutional investors sold positions of 2,942,426 shares during the same period.